Market Place
Sourcing Support
Janux Closes $402.5M Public Offering with Full Over-Allotment
06 Dec 2024 //
BUSINESSWIRE
Janux Prices $350M Public Offering Of Stock & Pre-Funded Warrants
04 Dec 2024 //
BUSINESSWIRE
Janux Therapeutics Announces Proposed Public Offering
03 Dec 2024 //
BUSINESSWIRE
Janux Doses Selected for Phase 1b Expansion of JANX007 in mCRPC
02 Dec 2024 //
BUSINESSWIRE
Janux Therapeutics to Host Virtual Event on JANX007 Data in mCRPC
25 Nov 2024 //
BUSINESSWIRE
Janux Therapeutics Reports Q3 2024 Results & Business Update
06 Nov 2024 //
BUSINESSWIRE
Janux Therapeutics Reports Q2 2024 Results And Business Highlights
07 Aug 2024 //
BUSINESSWIRE
Janux Therapeutics Announces Updates to Board of Directors
22 Jul 2024 //
BUSINESSWIRE
Janux Therapeutics Q1 2024 Results And Highlights
07 May 2024 //
BUSINESSWIRE
Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal
29 Apr 2024 //
SEEKINGALPHA
Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale
11 Apr 2024 //
BLOOMBERG
Alpine Immune Sciences, Janux said to be looking at possible sales — reports
10 Apr 2024 //
ENDPTS
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
08 Mar 2024 //
BUSINESSWIRE
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound and CleanSpark
04 Mar 2024 //
YAHOO FINANCE
Janux Announces Pricing of $296.5 Million Underwritten Public Offering
29 Feb 2024 //
PRESS RELEASE
Janux Therapeutics surges on upbeat trial data for prostate cancer therapy
28 Feb 2024 //
ENDPTS
Janux Therapeutics Announces Proposed Public Offering of Common Stock
27 Feb 2024 //
PRESS RELEASE
Janux Announces Safety Data in Escalation Trials for PSMAxCD3-TRACTr JANX007
26 Feb 2024 //
BUSINESSWIRE
Janux Therapeutics to Host Virtual Event Discussing Data for PSMA-TRACTr JANX007
20 Feb 2024 //
BUSINESSWIRE
Janux Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
08 Jan 2024 //
BUSINESSWIRE
Janux Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
Janux Reports Second Quarter 2023 Financial Results and Business Highlights
08 Aug 2023 //
BUSINESSWIRE
Janux Announces Positive Data from Ph 1a Dose Escalation for PSMA-TRACTr JANX007
17 Jul 2023 //
BUSINESSWIRE
Janux Announces Pricing of $60 Million Underwritten Offering of Common Stock
17 Jul 2023 //
BUSINESSWIRE
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President
05 Jun 2023 //
BUSINESSWIRE
Janux Therapeutics Reports1Q 2023 FYR and Business Highlights
09 May 2023 //
BUSINESSWIRE
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
24 Apr 2023 //
BUSINESSWIRE
Janux Therapeutics Announces First Patient Dosed with JANX008
20 Apr 2023 //
BUSINESSWIRE
Janux Reports Fourth Quarter and Full Year 2022 Financial Results
10 Mar 2023 //
BUSINESSWIRE
Janux to Participate in Novel IO Panel Discussion at Cowen`s Annual Conference
14 Feb 2023 //
BUSINESSWIRE
Janux Therapeutics Announces Submission of i NDA for JANX008
27 Dec 2022 //
BUSINESSWIRE
Janux Therapeutics to Present at Upcoming Investor Conferences in November
22 Nov 2022 //
BUSINESSWIRE
Janux Therapeutics Reports 3Q 2022 Financial Results and Business Highlights
10 Nov 2022 //
BUSINESSWIRE
Janux Announces First Patient Dosed with JANX007 in First-in-Human PhI Trial
12 Oct 2022 //
BUSINESSWIRE
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
23 Sep 2022 //
BUSINESSWIRE
Janux Therapeutics Appoints Winston Kung to Board of Directors
22 Sep 2022 //
BUSINESSWIRE
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences
31 Aug 2022 //
BUSINESSWIRE
Janux Therapeutics Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
02 Jun 2022 //
BUSINESSWIRE
Janux Announces FDA Clearance of IND for JANX007 in Prostate Cancer
31 May 2022 //
BUSINESSWIRE
Janux Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
BUSINESSWIRE
Janux Therapeutics to Present Preclinical Data for PSMA-TRACTr, EGFR-TRACTr
26 Apr 2022 //
BUSINESSWIRE
Janux Tx Reports Q4 and FY 2021 Financial Results
18 Mar 2022 //
BUSINESSWIRE
Janux Tx to Present at Upcoming March Investor Conferences
01 Mar 2022 //
BUSINESSWIRE
Janux to Present Virtually at the H.C. Wainwright Investor Conference
07 Sep 2021 //
BUSINESSWIRE
Janux Therapeutics Reports Second Quarter 2021 Financial Results
10 Aug 2021 //
BUSINESSWIRE
Janux Therapeutics Appoints Shahram Salek-Ardakani
19 Jul 2021 //
BUSINESSWIRE
Janux Therapeutics Announces Closing of Initial Public Offering
15 Jun 2021 //
BUSINESSWIRE
Janux Therapeutics Announces Pricing of Initial Public Offering
11 Jun 2021 //
BUSINESSWIRE
Janux Therapeutics Announces Pricing of Initial Public Offering
11 Jun 2021 //
BUSINESSWIRE
Janux Therapeutics Announces Pricing of Initial Public Offering
11 Jun 2021 //
BUSINESSWIRE
Janux Therapeutics Announces Pricing of Initial Public Offering
10 Jun 2021 //
BUSINESSWIRE
Cancer Biotech Janux Therapeutics Files for $100 Million IPO
28 May 2021 //
BIOSPACE
Months after bursting into the bispecific scene out of nowhere, Janux follows
21 May 2021 //
ENDPTS
Janux Therapeutics raises funding to advance T cell engager treatments
21 Apr 2021 //
PHARMACEUTICAL-TECHNOLOGY
RA Capital leads $125M for Janux in VC`s latest crossover bid
20 Apr 2021 //
ENDPTS
Janux Closes $125 Million Series B Financing to Advance Next Generation
20 Apr 2021 //
BUSINESSWIRE
Janux Appoints Vickie Capps & Dr. Sheila Gujrathi to Board of Directors
18 Mar 2021 //
BUSINESSWIRE
Janux Therapeutics Appoints Andy Meyer Chief Business Officer
15 Mar 2021 //
OAOA
Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug
03 Mar 2021 //
BUSINESSWIRE
